GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » EV-to-Revenue

Oncodesign Precision Medicine (XPAR:ALOPM) EV-to-Revenue : 36.14 (As of Jun. 23, 2025)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oncodesign Precision Medicine's enterprise value is €7.48 Mil. Oncodesign Precision Medicine's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €0.21 Mil. Therefore, Oncodesign Precision Medicine's EV-to-Revenue for today is 36.14.

The historical rank and industry rank for Oncodesign Precision Medicine's EV-to-Revenue or its related term are showing as below:

XPAR:ALOPM' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.58   Med: 14.46   Max: 73.65
Current: 36.14

During the past 5 years, the highest EV-to-Revenue of Oncodesign Precision Medicine was 73.65. The lowest was 0.58. And the median was 14.46.

XPAR:ALOPM's EV-to-Revenue is ranked worse than
76.38% of 995 companies
in the Biotechnology industry
Industry Median: 7.67 vs XPAR:ALOPM: 36.14

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-23), Oncodesign Precision Medicine's stock price is €0.285. Oncodesign Precision Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.01. Therefore, Oncodesign Precision Medicine's PS Ratio for today is 23.75.


Oncodesign Precision Medicine EV-to-Revenue Historical Data

The historical data trend for Oncodesign Precision Medicine's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine EV-to-Revenue Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
- - 2.18 26.68 73.80

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial 2.18 - 26.68 - 73.80

Competitive Comparison of Oncodesign Precision Medicine's EV-to-Revenue

For the Biotechnology subindustry, Oncodesign Precision Medicine's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's EV-to-Revenue falls into.


;
;

Oncodesign Precision Medicine EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Oncodesign Precision Medicine's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=7.481/0.207
=36.14

Oncodesign Precision Medicine's current Enterprise Value is €7.48 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oncodesign Precision Medicine's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncodesign Precision Medicine  (XPAR:ALOPM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Oncodesign Precision Medicine's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.285/0.012
=23.75

Oncodesign Precision Medicine's share price for today is €0.285.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was €0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncodesign Precision Medicine EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine Business Description

Traded in Other Exchanges
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines